The AIDS Drug Assistance Programs (ADAP) Advocacy organization has embarked on a significant national advocacy campaign aimed at reforming the 340B Drug Pricing Program. This initiative, underscored by a targeted commercial in the Washington, D.C. area, seeks to address critical issues within the program's current framework. Brandon M. Macsata, CEO of ADAP Advocacy, emphasizes the campaign's focus on the lack of accountability and transparency, especially among large hospital systems, under the banner '340B Too Big To Fail'.
The timing of the commercial, airing during Congress's session, is strategic, aiming to spark discussions on the program's oversight and inherent risks. Macsata draws a stark comparison between the 340B Program's current state and the minimal federal oversight that contributed to the 2007-2008 financial market collapse, hinting at possible systemic vulnerabilities that could have far-reaching implications.
Throughout the year, the campaign will delve into pressing issues such as the decline in hospitals' charity care, the rise in healthcare executive compensation, and the increasing strain of patient medical debt. Given its position as the second-largest federally sponsored drug program, trailing only Medicare Part D, the 340B Program stands as a pivotal area for systemic reform. The campaign is rooted in the findings and suggestions of the ADAP Advocacy's 340B Patient Advisory Committee, aiming to foster a constructive dialogue on healthcare pricing and accessibility.
For more information on the 340B Program and its impact, visit https://www.hrsa.gov/opa.
